Ray Dalio
SRPT icon

Ray Dalio’s Sarepta Therapeutics SRPT Stock Holding History

Ray Dalio’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.92M Sell
134,277
-146,291
-52% -$2.83M 0.01% 567
2025
Q4 		$6.04M Sell
280,568
-71,707
-20% -$1.51M 0.02% 477
2025
Q3 		$6.79M Buy
+352,275
New +$6.28M 0.03% 419
2025
Q2 		– Sell
-19,820
Closed -$1.26M – 716
2025
Q1 		$1.26M Buy
19,820
+14,575
+278% +$1.53M 0.01% 500
2024
Q4 		$638K Buy
+5,245
New +$643K ﹤0.01% 555
2024
Q2 		– Sell
-23,222
Closed -$3.01M – 933
2024
Q1 		$3.01M Sell
23,222
-3,166
-12% -$388K 0.02% 440
2023
Q4 		$2.54M Sell
26,388
-24,076
-48% -$2.31M 0.01% 480
2023
Q3 		$6.12M Buy
50,464
+19,608
+64% +$2.22M 0.04% 316
2023
Q2 		$3.53M Buy
30,856
+386
+1% +$49.8K 0.02% 371
2023
Q1 		$4.2M Sell
30,470
-27,465
-47% -$3.56M 0.03% 344
2022
Q4 		$7.51M Sell
57,935
-40,473
-41% -$4.69M 0.04% 287
2022
Q3 		$10.9M Sell
98,408
-27,110
-22% -$2.73M 0.06% 243
2022
Q2 		$9.41M Buy
125,518
+121,144
+2,770% +$8.91M 0.04% 344
2022
Q1 		$342K Buy
+4,374
New +$335K ﹤0.01% 927
2021
Q3 		– Sell
-3,838
Closed -$298K – 788
2021
Q2 		$298K Sell
3,838
-370
-9% -$28.1K ﹤0.01% 685
2021
Q1 		$314K Buy
+4,208
New +$388K ﹤0.01% 414

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ray Dalio's SRPT Position: Q1 2026 in Review

Ray Dalio reduced its Sarepta Therapeutics (SRPT) stake by 52% in Q1 2026, selling an estimated $2.83M and leaving 134,277 shares worth $2.92M. The position accounts for 0.01% of the portfolio, ranked #567.

Ray Dalio first reported a position in SRPT in Q1 2021 and has held it in 16 quarters since. The position peaked at $10.9M in Q3 2022. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Ray Dalio held 134,277 shares of Sarepta Therapeutics worth $2.92M as of Q1 2026.
  • Ray Dalio sold 146,291 Sarepta Therapeutics shares in Q1 2026, an estimated $2.83M.
  • Sarepta Therapeutics made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #567 holding.
  • Ray Dalio first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Ray Dalio's Sarepta Therapeutics position peaked at $10.9M in Q3 2022.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.